As of July 1, 2023, Baizi Shenzhou is the only company listed on the A-share Kechuan Board, the U.S. Nasdaq, and Hong Kong, and is a company specializing in research and development of drugs to treat cancer. Its parent company is registered in the Cayman Islands, setting a precedent for foreign companies to list on the A-share market.